iXpressGenes
Private Company
Funding information not available
Overview
iXpressGenes operates at the intersection of genetics, genomics, and synthetic biology, offering diagnostic panels that analyze upstream RNA-based biomarkers. The company targets the growing market for personalized health by providing objective data that complements existing tools like GLP-1 medications, CGMs, and wearables. Its business model is focused on serving B2B clients, including medical weight loss clinics, athletic performance organizations, and digital health platforms, aiming to reduce client churn and create recurring revenue through retesting. Founded in 2015, iXpressGenes is positioned as a commercial-stage diagnostics and services provider.
Technology Platform
RNA-based blood analysis platform quantifying gene expression related to inflammation, physiological load, and metabolic adaptation. Offers interpretation-ready biomarker panels (TAI, APX, WLR) for B2B integration.
Opportunities
Risk Factors
Competitive Landscape
iXpressGenes competes in the advanced biomarker testing space against large diagnostic labs (e.g., Quest, LabCorp) expanding wellness panels, other multi-omics startups, and companies offering metabolomics or proteomics-based health insights. Its differentiation lies in its specific focus on RNA-based upstream signals, B2B workflow integration, and targeting of the performance and GLP-1 clinic niches.